Pfizer Market Cap 2012-2026 | PFE

Pfizer market cap history and chart from 2012 to 2026. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Pfizer market cap as of September 14, 2026 is $157.99B.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $157.995B $62.579B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $1071.528B 36.15
Johnson & Johnson (JNJ) United States $641.804B 24.52
AbbVie (ABBV) United States $462.493B 24.08
Merck (MRK) United States $357.370B 45.12
Roche Holding AG (RHHBY) Switzerland $349.105B 0.00
Novartis AG (NVS) Switzerland $265.214B 16.01
Novo Nordisk (NVO) Denmark $194.004B 10.81
Sanofi (SNY) France $105.050B 8.84
Bayer (BAYRY) Germany $56.081B 9.98
Innoviva (INVA) United States $1.510B 5.16